HDAX Therapeutics Analysis: $5M Raised
What is HDAX Therapeutics?
Proprietary 2-site HDAC6 binding technology for neurology and cardiovascular diseases
HQ Country
Mississauga, Canada
Employees
11-50
Founded
2021
HQ State/Province
On
Funding Category
Seed
HQ Full Address
Mississauga, On, Canada
Other Considerations
None available
Product Features & Capabilities
- 2-site HDAC6 binding small molecules
- Targeted therapy for neuropathies and cardiovascular diseases
- Enhanced drug selectivity and safety profile
